Saga Communications (SGA) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.14 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 24.24%. A quarter ago, it was expected that this broadcasting company would post a loss of $0.12 per share when it actually produced earnings of $0.20, delivering a surprise of 266.67%.Over the last four quarters, the c ...

Group 1: Earnings Performance - Capital Clean Energy Carriers Corp. (CCEC) reported quarterly earnings of $0.55 per share, exceeding the Zacks Consensus Estimate of $0.36 per share, and up from $0.32 per share a year ago, representing an earnings surprise of 52.78% [1] - The company posted revenues of $108.14 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 2.20%, compared to year-ago revenues of $100.64 million [2] Group 2: Stock Performance and Market Comparison - CCEC shares have increased approximately 9.5% since the beginning of the year, while the S&P 500 has declined by 4.3% [3] - The current consensus EPS estimate for the upcoming quarter is $0.37 on revenues of $105.02 million, and for the current fiscal year, it is $1.52 on revenues of $429.38 million [7] Group 3: Industry Outlook - The Transportation - Shipping industry, to which CCEC belongs, is currently ranked in the bottom 11% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor sentiment and stock performance [5]

Core Viewpoint - Vital Farms reported quarterly earnings of $0.37 per share, exceeding the Zacks Consensus Estimate of $0.26 per share, but down from $0.43 per share a year ago, indicating a 13.95% year-over-year decline in earnings [1] - The company has consistently surpassed consensus EPS estimates over the last four quarters, with a notable earnings surprise of 42.31% this quarter [2][1] Financial Performance - Vital Farms posted revenues of $162.19 million for the quarter ended March 2025, which was a 9.63% increase from $147.93 million year-over-year, but missed the Zacks Consensus Estimate by 0.27% [2] - The company has topped consensus revenue estimates three times in the last four quarters [2] Stock Performance - Vital Farms shares have declined approximately 4.7% year-to-date, compared to a 4.3% decline in the S&P 500 [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.28, with projected revenues of $170.93 million, and for the current fiscal year, the estimate is $1.23 on revenues of $740.79 million [7] - The trend of earnings estimate revisions is mixed, which could change following the recent earnings report [6] Industry Context - The Food - Miscellaneous industry, to which Vital Farms belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Company Performance - Monte Rosa Therapeutics reported quarterly earnings of $0.57 per share, significantly beating the Zacks Consensus Estimate of a loss of $0.24 per share, and improving from a loss of $0.53 per share a year ago, representing an earnings surprise of 337.50% [1] - The company achieved revenues of $84.93 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 235.52%, compared to revenues of $1.06 million in the same quarter last year [2] - Over the last four quarters, Monte Rosa Therapeutics has consistently surpassed consensus EPS and revenue estimates [2] Stock Performance - Monte Rosa Therapeutics shares have declined approximately 44.5% since the beginning of the year, contrasting with the S&P 500's decline of 4.3% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.27 on revenues of $25.52 million, and for the current fiscal year, it is -$1.33 on revenues of $97.44 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Monte Rosa Therapeutics belongs, is currently ranked in the top 33% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]

Group 1 - Stratasys reported quarterly earnings of $0.04 per share, exceeding the Zacks Consensus Estimate of $0.03 per share, compared to a loss of $0.02 per share a year ago, representing an earnings surprise of 33.33% [1] - The company posted revenues of $136.05 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 0.84%, but down from $144.05 million year-over-year [2] - Stratasys shares have increased approximately 9.3% since the beginning of the year, while the S&P 500 has declined by 4.3% [3] Group 2 - The current consensus EPS estimate for the upcoming quarter is $0.05 on revenues of $137.88 million, and for the current fiscal year, it is $0.29 on revenues of $566.23 million [7] - The Commercial Printing industry, to which Stratasys belongs, is currently ranked in the top 24% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] Group 3 - Stratasys has surpassed consensus EPS estimates three times over the last four quarters and has topped consensus revenue estimates two times in the same period [2] - The estimate revisions trend for Stratasys is mixed, resulting in a Zacks Rank 3 (Hold) for the stock, suggesting it is expected to perform in line with the market in the near future [6]

Company Performance - The Real Brokerage Inc. reported a quarterly loss of $0.02 per share, better than the Zacks Consensus Estimate of a loss of $0.05, and improved from a loss of $0.04 per share a year ago, representing an earnings surprise of 60% [1] - The company posted revenues of $353.98 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 7.65%, and up from $200.74 million in the same quarter last year [2] - Over the last four quarters, the company has surpassed consensus EPS estimates four times and topped consensus revenue estimates four times [2] Stock Outlook - The Real Brokerage shares have declined approximately 2.8% since the beginning of the year, compared to a decline of 4.3% for the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $444.15 million, and for the current fiscal year, it is -$0.10 on revenues of $1.67 billion [7] - The estimate revisions trend for The Real Brokerage is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Technology Services industry, to which The Real Brokerage belongs, is currently ranked in the top 27% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Insights - Warner Bros. Discovery reported a quarterly loss of $0.18 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.12, but an improvement from a loss of $0.40 per share a year ago [1][2] - The company's revenues for the quarter were $8.98 billion, missing the Zacks Consensus Estimate by 7.34% and down from $9.96 billion year-over-year [3] - The stock has underperformed the market, losing about 19% since the beginning of the year compared to the S&P 500's decline of 4.3% [4] Financial Performance - The earnings surprise for the latest quarter was -50%, and the company has only surpassed consensus EPS estimates once in the last four quarters [2] - The current consensus EPS estimate for the upcoming quarter is -$0.19 on revenues of $9.72 billion, and for the current fiscal year, it is -$0.14 on revenues of $38.68 billion [8] Industry Context - Warner Bros. Discovery operates within the Zacks Broadcast Radio and Television industry, which is currently ranked in the top 38% of over 250 Zacks industries [9] - The industry outlook can significantly impact the stock's performance, with research indicating that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [9] Future Outlook - The estimate revisions trend for Warner Bros. Discovery is currently unfavorable, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [7] - The upcoming earnings call will be crucial for assessing future earnings expectations and stock price movements [4][5]

Core Insights - Xeris Biopharma reported a quarterly loss of $0.06 per share, better than the Zacks Consensus Estimate of a loss of $0.07, and improved from a loss of $0.14 per share a year ago, representing an earnings surprise of 14.29% [1] - The company achieved revenues of $60.12 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 4.76% and up from $40.64 million year-over-year [2] - Xeris Biopharma's stock has increased by approximately 32.2% since the beginning of the year, contrasting with a decline of -4.3% in the S&P 500 [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.04 on revenues of $63.36 million, and for the current fiscal year, it is -$0.11 on revenues of $264.52 million [7] - The estimate revisions trend for Xeris Biopharma is favorable, leading to a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Drugs industry, to which Xeris Biopharma belongs, is currently ranked in the top 26% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8] - Another company in the same industry, Zevra Therapeutics, is expected to report a quarterly loss of $0.21 per share, with revenues anticipated to be $15.8 million, reflecting a significant year-over-year increase of 360.6% [9][10]

P10, Inc. (PX) came out with quarterly earnings of $0.20 per share, missing the Zacks Consensus Estimate of $0.21 per share. This compares to earnings of $0.21 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -4.76%. A quarter ago, it was expected that this company would post earnings of $0.26 per share when it actually produced earnings of $0.30, delivering a surprise of 15.38%.Over the last four quarters, the company has surp ...

InfuSystems Holdings, Inc. (INFU) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.05 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 66.67%. A quarter ago, it was expected that this company would post earnings of $0.08 per share when it actually produced earnings of $0.04, delivering a surprise of -50%.Over the last four quarters, the company ...